The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech.
NextCure will use the series B funds to advance Siglec-15-targeting antibody NC318 and another asset through early-phase clinical development.
Kymera Therapeutics raised $65 million in series B funding that will support the clinical development of its lead protein degradation program.
Ribometrix raised $30 million to fund its platform that fits small molecules into the 3D folds and pockets of RNA structures to modulate their activity.
Two years after Nestlé Health Science poured $145 million into Aimmune, the company is boosting its total investment in the biotech to $273 million.
Quantum Genomics’ blood pressure drug firibastat met its endpoints in a phase 2b study, paving the way for a wider trial in resistant hypertension.
Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
Patrick Soon-Shiong’s NantKwest unit has reported the first data for its “cancer memory vaccine,” but it has some analysts scratching their heads.
Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.